Texto completo (381)
- Antivirales (468)
- Gripe Humana (417)
- Subtipo H1N1 del Virus de la Influenza A (158)
- Virus de la Influenza A (87)
- Brotes de Enfermedades (74)
- Farmacorresistencia Viral (64)
- Oseltamivir (52)
- Neuraminidasa (52)
- Vacunas contra la Influenza (46)
- Orthomyxoviridae (36)
- Subtipo H3N2 del Virus de la Influenza A (36)
- Subtipo H5N1 del Virus de la Influenza A (36)
- Infecciones por Orthomyxoviridae (35)
- Virus de la Influenza B (25)
- Pandemias (25)
- Inhibidores Enzimáticos (22)
- Gripe Aviar (22)
- Zanamivir (21)
- Proteínas Virales (16)
- Amantadina (16)
- Mostrar más...
- PLoS One (28)
- Antiviral Res (25)
- Influenza Other Respir Viruses (20)
- J Infect Dis (19)
- Clin Infect Dis (18)
- J Virol (12)
- Med Lett Drugs Ther (11)
- J Clin Virol (9)
- Wkly Epidemiol Rec (9)
- Ann Intern Med (8)
- Antimicrob Agents Chemother (8)
- Emerg Infect Dis (8)
- J Antimicrob Chemother (8)
- Vopr Virusol (8)
- J Immunol (7)
- Pediatr Infect Dis J (7)
- Lancet (6)
- Antibiot Khimioter (5)
- Antivir Ther (5)
- Biosecur Bioterror (5)
- Mostrar más...
Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015.
Fuente: Clin Infect Dis;2016 Nov 10.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 28013261
Resumen: Using population-based surveillance data, we analyzed antiviral treatment among hospitalized patients with laboratory-confirmed influenza. Treatment increased after the influenza A(H1N1) 2009 pandemic from 72% in 2010-2011 to 89% in 2014-2015 (P < .001). Overall, treatment was higher in adults (86%) than in children (72%); only 56% of cases received antivirals on the day of admission.
Homeopathy in disguise. Comment on Don et al.: Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.
Fuente: J Med Virol;2016 Dec 30.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 28036105
Resumen: The study «Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model¼ [Don et al., 2016] recently published in Journal of Medical Virology raises a number of concerns. We discuss these concerns in detail. This article is protected by copyright. All rights reserved.
The phenomenon of released-activity. Reply on comment on Don et al.: Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model.
Fuente: J Med Virol;2016 Dec 30.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 28036118
Resumen: This text is aimed to provide the readers with detailed information about phenomenon of released-activity and reply on the specific risen questions. This article is protected by copyright. All rights reserved.
Antiviral activity of hydroalcoholic extract from Eupatorium perfoliatum L. against the attachment of influenza A virus.
Fuente: J Ethnopharmacol;188: 144-52, 2016 Jul 21.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27178637
Resumen: ETHNOPHARMACOLOGICAL RELEVANCE: Aerial parts of Eupatorium perfoliatum have been traditionally used by American natives as a treatment for fever and infections. Also modern phytotherapy in Europe documents the use of hydroalcoholic extracts of this herbal material for the treatment of infections of the upper respiratory tract. AIM OF THE STUDY: The aim of the present study was to characterize the anti-influenza A virus (IAV) potential of extracts derived from the aerial parts of E. perfolia (mas)
Fuente: Proc Natl Acad Sci U S A;113(14): 3861-6, 2016 Apr 05.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27001854
Resumen: A brief window of antigen-nonspecific protection has been observed after influenza A virus (IAV) infection. Although this temporary immunity has been assumed to be the result of residual nonspecific inflammation, this period of induced immunity has not been fully studied. Because IAV has long been characterized as a cytopathic virus (based on its ability to rapidly lyse most cell types in culture), it has been a forgone conclusion that directly infected cells could not be contributing to th (mas)
In vitro and in vivo mechanism of immunomodulatory and antiviral activity of Edible Bird's Nest (EBN) against influenza A virus (IAV) infection.
Fuente: J Ethnopharmacol;185: 327-40, 2016 Jun 05.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26976767
Resumen: ETHNOPHARMACOLOGICAL RELEVANCE: For centuries, Edible Bird Nest (EBN) has been used in treatment of variety of respiratory diseases such as flu and cough as a Chinese natural medicine. AIM OF THE STUDY: This natural remedy showed the potential to inhibit influenza A virus (IAV). However, little is known about the mechanism of this process and also the evaluation of this product in an animal model. Hence, the current study was designed to elucidate the antiviral and immunomodulatory effects (mas)
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
Fuente: Antiviral Res;129: 21-38, 2016 May.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26872862
Resumen: The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4th Antiviral Group Conference at the University of Texas on 2-4 June, 2015. With emerging resistance to the drugs currently licensed for treatment and prophylaxis of influenza viruses, primarily the neuraminidase inhibitor oseltamivir phosphate (Tamiflu) and the M2 inhibitors amantadine and rimantadine, and the lack of effective interventions against other respiratory viruses, the 3-day programme (mas)
Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral.
Fuente: Antivir Ther;21(1): 71-4, 2016.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26133231
Resumen: We report a cystic fibrosis patient infected with influenza 2009H1N1 who had persistent viral shedding and clinical deterioration despite prolonged treatment with oseltamivir and zanamivir. The patient was diagnosed with H275Y neuraminidase inhibitor resistant influenza during treatment, thus was treated for 10 days with DAS181, an investigational host-directed inhaled sialidase fusion protein. Viral clearance occurred after 5 days of therapy and the patient became eligible for lung transpl (mas)
Cost-effectiveness analysis of antiviral treatment in the management of seasonal influenza A: point-of-care rapid test versus clinical judgment.
Fuente: Influenza Other Respir Viruses;10(2): 113-21, 2016 Mar.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26574910
Resumen: BACKGROUND: A point-of-care rapid test (POCRT) may help early and targeted use of antiviral drugs for the management of influenza A infection. OBJECTIVE: (i) To determine whether antiviral treatment based on a POCRT for influenza A is cost-effective and, (ii) to determine the thresholds of key test parameters (sensitivity, specificity and cost) at which a POCRT based-strategy appears to be cost effective. METHODS: An hybrid « susceptible, infected, recovered (SIR) ¼ compartmental transmis (mas)
Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Fuente: Antiviral Res;127: 68-78, 2016 Mar.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26802558
Resumen: A target-free and cell-based approach was applied to evaluate the anti-influenza properties of six newly synthesized benzoic acid derivatives. SA-2, the ethyl 4-(2-hydroxymethyl-5-oxopyrrolidin-1-yl)-3-[3-(3-methylbenzoyl)-thioureido] benzoate (compound 2) was screened as a potential drug candidate. In a cytopathic effect assay, SA-2 dose dependently inhibited H1N1, H3N2 and the oseltamivir-resistant mutant H1N1-H275Y influenza viruses in both virus-infected MDCK and A549 cells, with 50% ef (mas)
Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.
Fuente: PLoS One;11(1): e0145902, 2016.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26761707
Resumen: BACKGROUND: Influenza and its associated diseases are a major cause of morbidity and mortality. The United States Advisory Committee on Immunization Practices recommends influenza vaccination for everyone over 6 months of age. The failure of the flu vaccine in 2014-2015 demonstrates the need for a model that allows the rapid development of novel antivirals, universal/intra-seasonal vaccines, immunomodulators, monoclonal antibodies and other novel treatments. To this end we manufactured a ne (mas)
Oligomerization and GTP-binding Requirements of MxA for Viral Target Recognition and Antiviral Activity against Influenza A Virus.
Fuente: J Biol Chem;290(50): 29893-906, 2015 Dec 11.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26507657
Resumen: The IFN-induced human myxovirus resistance protein A (MxA) exhibits a broad antiviral activity against many viruses, including influenza A virus (IAV). MxA belongs to the family of dynamin-like GTPases and assembles in vitro into dimers, tetramers, and oligomeric ring-like structures. The molecular mechanism of action remains to be elucidated. Furthermore, it is not clear whether MxA exerts its antiviral activity in a monomeric and/or multimeric form. Using a set of MxA mutants that form co (mas)